Skip to content
The African Exponent DATA
Resources

Review pending. Every figure has been located on its cited source page in an AI-assisted source verification (matched to OCR text of the page image; matched to OCR text and compared cell by cell with the page image; read from the page image) (17 October 2026). Independent review has not yet been carried out, and these pages are not indexed.AI-assisted source check done; independent review pending; not indexed. About the review

BIOPHARM

BIO · Bourse d'Alger (SGBV) · Consolidated statements

On this page
Company details
Legal name
BIOPHARM SPA
Listing
BIO on the Bourse d'Alger (SGBV), active (observed 2026-10-08)
Sector
Not classified (our classification from the stated principal activity)
Financial year ends
31 December

Overview

Year ended 31 December 2025 · annual report, signed / final · source

  • Revenue

    DZD 84.2 billion

    84,197 DZD millions · p36

    −1.5% vs 2024

  • Operating profit / (loss)

    DZD 11.4 billion

    11,407 DZD millions · p36

    +0.1% vs 2024

  • Profit / (loss) for the year

    DZD 9.47 billion

    9,469 DZD millions · p36

    −1.4% vs 2024

  • Total assets

    DZD 108 billion

    107,924 DZD millions · p37

    +11.4% vs 2024

  • Total equity

    DZD 64.8 billion

    64,787 DZD millions · p38

    +9.0% vs 2024

  • Cash from operations

    DZD 9.72 billion

    9,723 DZD millions · p39

    −17.3% vs 2024

Large amounts are rounded for reading (DZD million / billion / trillion); exact figures as printed are under each amount and in the tables. No currency conversion.

Financial statements

Exact figures as printed. Each column comes from one filing; labels are as printed in the newest filing. Amounts in DZD millions unless the row says otherwise; brackets are negative.

† from a supplementary filing for the same year · ‡ signed audited statements preferred over a disputed figure · “–” is a printed dash, explained below the table

Column sources

  • FY2025 — annual report, signed / final; reported for the year · source
  • FY2024 — annual report, signed / final; comparative in the FY2025 filing · source
  • FY2023 — annual report, signed / final; reported for the year · source
  • FY2022 — annual report, signed / final; comparative in the FY2023 filing · source

Income statement

Income statement, DZD millions. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025; FY2023 — annual report (signed / final), as reported for the year; FY2022 — annual report (signed / final), comparative reported in the annual report for 2023.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filingFY2023Annual reportreported for the yearFY2022Annual reportcomparative in FY2023 filing
Ventes et produits annexes 84,197 85,457 82,917 83,818
Variation stocks produits finis et en cours1 (578) 236 (59) 404
Production de l'exercice2 83,619 85,693 82,859 84,222
Achats consommés3 (62,585) (64,080) (62,542) (63,931)
Services extérieurs et autres consommations4 (2,844) (2,635) (2,434) (2,499)
Consommation de l'exercice5 (65,429) (66,714) (64,976) (66,431)
Valeur ajoutée6 18,190 18,979 17,883 17,791
Charges de personnel (4,925) (4,477) (4,405) (4,087)
Impôts, taxes et versements assimilés7 (265) (244) (905) (930)
Excédent brut d'exploitation8 13,000 14,257 12,573 12,774
Autres produits opérationnels 245 119 142 146
Autres charges opérationnelles (415) (347) (327) (294)
Dotations aux amortissements, provisions et pertes de valeurs910 (6,362) (6,192) (4,758) (4,146)
Reprise sur pertes de valeur et provisions11 4,939 3,560 3,132 1,840
Résultat opérationnel 11,407 11,398 10,762 10,320
Produits financiers 1,126 679 222 528
Charges financières (888) (376) (453) (499)
Résultat financier12 238 303 (231) 29
Résultat ordinaire avant impôt13 11,645 11,701 10,532 10,349
Impôts exigibles sur résultats ordinaires14 (2,165) (2,035) (1,818) (1,984)
Impôts différés (Variations ) sur résultats ordinaires1516 (10) (67) (208) 66
Résultat net des activités ordinaires17 9,469 9,599 8,505 8,431
Résultat extraordinaire18 –19 –19 –19 –19
Résultat net de l'exercice 9,469 9,599 8,505 8,431
Part des minoritaires20 Not reported in this filing21 Not reported in this filing21 33 (65)
  1. Printed “-”, read as nil: subtotal_arithmetic: is.profit_for_year.
Notes and alternative reported figures (20)
  1. “Variation stocks produits finis et en cours” is an issuer-specific line, not mapped to a shared definition: Change in finished goods and work in progress.
  2. “Production de l'exercice” is an issuer-specific line, not mapped to a shared definition: SCF subtotal: sales plus change in finished goods.
  3. “Achats consommés” is an issuer-specific line, not mapped to a shared definition: Purchases consumed (negative).
  4. “Services extérieurs et autres consommations” is an issuer-specific line, not mapped to a shared definition: Note 18 (negative).
  5. “Consommation de l'exercice” is an issuer-specific line, not mapped to a shared definition: SCF subtotal: purchases consumed and external services (negative).
  6. “Valeur ajoutée” is an issuer-specific line, not mapped to a shared definition: SCF subtotal: production less consumption.
  7. “Impôts, taxes et versements assimilés” is an issuer-specific line, not mapped to a shared definition: Note 20: taxes other than income tax (negative).
  8. “Excédent brut d'exploitation” is an issuer-specific line, not mapped to a shared definition: SCF subtotal: value added less staff costs and taxes.
  9. “Dotations aux amortissements, provisions et pertes de valeurs” is an issuer-specific line, not mapped to a shared definition: Depreciation, provisions and impairment charges (negative); note 22 printed between this line and the next.
  10. Printed under different labels across filings: “Dotations aux amortissements, provisions et pertes de valei”; “Dotations aux amortissements, provisions et pertes de valeurs”.
  11. “Reprise sur pertes de valeur et provisions” is an issuer-specific line, not mapped to a shared definition: Reversals of impairment and provisions.
  12. “Résultat financier” is an issuer-specific line, not mapped to a shared definition: Note 23: financial income less financial charges.
  13. Printed under different labels across filings: “Résultat ordinaire avant im pôt”; “Résultat ordinaire avant impôt”.
  14. “Impôts exigibles sur résultats ordinaires” is an issuer-specific line, not mapped to a shared definition: Note 24: current income tax (negative).
  15. “Impôts différés (Variations ) sur résultats ordinaires” is an issuer-specific line, not mapped to a shared definition: Deferred tax (negative).
  16. Printed under different labels across filings: “Impôts différés ( Variations ) sur résultats ordinaires”; “Impôts différés (Variations ) sur résultats ordinaires”.
  17. “Résultat net des activités ordinaires” is an issuer-specific line, not mapped to a shared definition: Net result of ordinary activities, after income tax.
  18. “Résultat extraordinaire” is an issuer-specific line, not mapped to a shared definition: Extraordinary items (printed '-' in both years).
  19. “Part des minoritaires” is an issuer-specific line, not mapped to a shared definition: Share of the net result attributable to minority interests.
  20. Not reported in this filing: Not printed: the FY2025 compte de résultat consolidé (p36, image page) ends with 'Résultat net de l'exercice' 9 469 / 9 599 and 'Dont Part du Groupe' 9 413 / 9 529; there is no 'Part des minoritaires' line. Checked on the page image (the stored text layer of these pages holds only headings).

Balance sheet

Balance sheet, DZD millions. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025; FY2023 — annual report (signed / final), as reported for the year; FY2022 — annual report (signed / final), comparative reported in the annual report for 2023.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filingFY2023Annual reportreported for the yearFY2022Annual reportcomparative in FY2023 filing
Ecart d'acquisition - goodwill positif ou négatif12 683 683 703 703
Immobilisations incorporelles 193 210 146 127
Terrains3 2,018 2,018 2,018 2,018
Bâtiments4 2,354 675 750 500
Autres immobilisations corporelles5 5,775 5,157 5,357 5,244
Immobilisations en concession6 –7 –7 –7 –7
Immobilisations encours8 14,806 15,104 13,358 9,096
Titres mis en équivalence –7 –7 –7 –7
Autres participations et créances rattachées9 178 105 5 5
Autres titres immobilisés10 15,843 2,000 –7 –7
Prêts et autres actifs financiers non courants11 422 5,438 6,464 36
Impôts différés actif 570 534 543 801
Total actifs non courants 42,842 31,924 29,345 18,529
Stocks et encours 24,286 24,001 23,824 22,303
Clients 26,253 27,120 28,946 26,409
Autres débiteurs12 5,439 5,095 4,890 5,261
Impôts et assimilés 2,536 2,410 2,542 2,071
Autres créances et emplois assimilés13 –14 –14 –14 –14
Placements et autres actifs financiers courants15 2,000 2,000 –14 –14
Trésorerie 4,569 4,303 5,366 8,121
Total actifs courants 65,083 64,928 65,569 64,166
Total actifs 107,924 96,852 94,914 82,694
Capital émis 5,104 5,104 5,104 5,104
Capital non appelé16 –17 –17 –17 –17
Primes et réserves - Réserves consolidés (1)18 19,757 16,784 14,280 12,512
Ecart de réévaluation –17 –17 Not reported in this filing19 Not reported in this filing19
Ecart d'équivalence (1)20 –17 –17 Not reported in this filing21 Not reported in this filing21
Résultat net - Résultat net du groupe (1)22 9,469 9,599 8,505 8,431
Autres capitaux propores - Report à nouveau 30,456 27,925 26,478 23,210
Part de la société consolidante (1) 64,222 58,904 53,934 49,016
Part des minoritaires (1) 565 509 433 242
Total Capitaux propores 64,787 59,413 54,367 49,258
Emprunts et dettes financières 6,206 5,213 7,818 2,796
Impôts (diférés et provisionnés)2324 584 538 481 530
Autres dettes non courantes25 –26 –26 –26 –26
Provisions et produits constatés d'avance27 –26 –26 –26 20
Total passifs non courants 6,790 5,751 8,299 3,346
Fournisseurs et comptes rattachés 17,667 20,281 19,300 18,203
Impôts 1,919 1,747 1,538 1,530
Autres dettes28 5,466 4,100 6,004 6,072
Trésorerie passif29 11,296 5,560 5,406 4,286
Total passifs courants 36,348 31,688 32,248 30,091
Total passifs et capitaux propres 107,924 96,852 94,914 82,694
  1. Printed “-”, read as nil: subtotal_arithmetic: bs.non_current_assets.
  2. Printed “-”, read as nil: subtotal_arithmetic: bs.current_assets.
  3. Printed “-”, read as nil: subtotal_arithmetic: bs.total_equity.
  4. Printed “-”, read as nil: subtotal_arithmetic: bs.non_current_liabilities.
Notes and alternative reported figures (25)
  1. “Ecart d'acquisition - goodwill positif ou négatif” is an issuer-specific line, not mapped to a shared definition: Note 1: goodwill.
  2. Printed under different labels across filings: “Ecart d'acquisition - goodwill positif ou négatif”; “Ecart d'acquisition - goodwill positif ou néç”.
  3. “Terrains” is an issuer-specific line, not mapped to a shared definition: Tangible fixed assets (note 2.2): land.
  4. “Bâtiments” is an issuer-specific line, not mapped to a shared definition: Tangible fixed assets (note 2.2): buildings.
  5. “Autres immobilisations corporelles” is an issuer-specific line, not mapped to a shared definition: Tangible fixed assets (note 2.2): other.
  6. “Immobilisations en concession” is an issuer-specific line, not mapped to a shared definition: Tangible fixed assets (note 2.2): assets held in concession (printed '-').
  7. “Immobilisations encours” is an issuer-specific line, not mapped to a shared definition: Note 3: fixed assets in progress.
  8. “Autres participations et créances rattachées” is an issuer-specific line, not mapped to a shared definition: Financial fixed assets (note 4).
  9. “Autres titres immobilisés” is an issuer-specific line, not mapped to a shared definition: Financial fixed assets (note 4).
  10. “Prêts et autres actifs financiers non courants” is an issuer-specific line, not mapped to a shared definition: Financial fixed assets (note 4).
  11. “Autres débiteurs” is an issuer-specific line, not mapped to a shared definition: Note 8: other receivables (supplier rebates and advances).
  12. “Autres créances et emplois assimilés” is an issuer-specific line, not mapped to a shared definition: Printed '-' in both years.
  13. Printed under different labels across filings: “Placements et autres actifs financiers courants”; “Placements et autres actifs financiers courar”.
  14. “Capital non appelé” is an issuer-specific line, not mapped to a shared definition: Uncalled capital (printed '-').
  15. “Primes et réserves - Réserves consolidés (1)” is an issuer-specific line, not mapped to a shared definition: Share premiums and consolidated reserves.
  16. Not reported in this filing: Not printed: the FY2023 bilan passifs (p39; actifs on p38, image pages) prints equity as 'Capital émis', 'Capital non appelé', 'Primes et réserves - Réserves consolidés (1)', 'Résultat net - Résultat net du groupe (1)', 'Autres capitaux propores - Report à nouveau', 'Part de la société consolidante (1)', 'Part des minoritaires (1)' and 'Total Capitaux propores'; there is no 'Ecart de réévaluation' line. Checked on the page image (the stored text layer of these pages holds only headings).
  17. “Ecart d'équivalence (1)” is an issuer-specific line, not mapped to a shared definition: Equity-method difference (printed '-').
  18. Not reported in this filing: Not printed: the FY2023 bilan passifs (p39; actifs on p38, image pages) prints equity as 'Capital émis', 'Capital non appelé', 'Primes et réserves - Réserves consolidés (1)', 'Résultat net - Résultat net du groupe (1)', 'Autres capitaux propores - Report à nouveau', 'Part de la société consolidante (1)', 'Part des minoritaires (1)' and 'Total Capitaux propores'; there is no 'Ecart d'équivalence' line. Checked on the page image (the stored text layer of these pages holds only headings).
  19. “Résultat net - Résultat net du groupe (1)” is an issuer-specific line, not mapped to a shared definition: The year's net result within equity (the printed amount equals the full net result, minority share included).
  20. “Impôts (diférés et provisionnés)” is an issuer-specific line, not mapped to a shared definition: Note 12: deferred and provisioned taxes (non-current).
  21. Printed under different labels across filings: “Impôts (différés et provisionnés)”; “Impôts (diférés et provisionnés)”.
  22. “Autres dettes non courantes” is an issuer-specific line, not mapped to a shared definition: Printed '-'.
  23. “Provisions et produits constatés d'avance” is an issuer-specific line, not mapped to a shared definition: Note 13 (non-current; printed '-').
  24. “Autres dettes” is an issuer-specific line, not mapped to a shared definition: Note 15: other current payables.
  25. “Trésorerie passif” is an issuer-specific line, not mapped to a shared definition: Note 16: bank facilities (discounting, overdrafts, letter-of-credit financing) and the part of long-term loans due within one year.

Cash flow

Cash flow, DZD millions. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025; FY2023 — annual report (signed / final), as reported for the year; FY2022 — annual report (signed / final), comparative reported in the annual report for 2023.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filingFY2023Annual reportreported for the yearFY2022Annual reportcomparative in FY2023 filing
Flux de trésorerie provenant des activités opérationnelles 9,723 11,760 6,306 8,118
Résultat net de l'exercice1 9,469 9,599 8,505 8,431
Dotations aux amortissements2 1,311 1,252 1,197 1,017
Dotations aux provisions et pertes de valeurs3 113 1,379 428 1,289
Variation impôts différés4 10 67 208 (66)
Plus ou Moins value de cession5 (2) (51) (15) (16)
Marge brute d'autofinancement6 10,901 12,246 10,324 10,655
Variation du Besoin en Fonds de Roulement7 (1,178) (487) (4,018) (2,537)
Variation de l'actif courant8 3,408 (7,082) (8,367) (5,727)
Variation du passif courant9 (4,587) 6,595 4,349 3,191
Flux de trésorerie prevenant des opérations d'investissement10 (12,135) (3,653) (11,445) (3,384)
Décaissements sur acquisition d'immobilisations (3,224) (2,606) (5,476) (3,561)
Encaissements sur cessions d'immobilisations 8 51 32 20
Variation des Titres de participation11 (73) (100) 0 0
Incidence des variations de périmètre12 –13 (1) –13 –13
Créances rattachées à des participations14 –13 –13 –13 –13
Variation des placements (DAT)15 (8,847) (996) (6,000) 157
Flux de trésorerie prevenant des opérations de financement16 (3,057) (7,324) 1,264 (5,641)
Emprunts 2,098 35 6,679 –17
Remboursement Emprunts (1,213) (2,640) (1,656) (1,364)
Compte courant d'associés18 14 –19 54 175
Augmentation de capital20 0 –19 35 3
Variation prêts et autres actifs financiers non courants21 19 23 (428) 11
Dividendes payés (4,084) (4,594) (3,420) (4,466)
Variation de trésorerie (5,470) 782 (3,875) (907)
Trésorerie d'ouverture 743 (39) 3,836 4,743
Trésorerie de clôture (4,727) 743 (39) 3,836
Variation des dettes à long terme22 Not reported in this filing23 Not reported in this filing23 –17 –17
Variation des dettes à court terme24 Not reported in this filing25 Not reported in this filing25 –17 –17
Variation Intérêts courus non échus (compte 518)26 Not reported in this filing27 Not reported in this filing27 0 –17
Subvention reçue28 Not reported in this filing29 Not reported in this filing29 –17 –17
  1. Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_investing.
  2. Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_financing.
  3. Printed “-”; reading unresolved, so no amount is shown. Printed dash; the printed financing lines do not add to the printed total (issuer inconsistency), so arithmetic cannot confirm a nil.
Notes and alternative reported figures (26)
  1. “Résultat net de l'exercice” is an issuer-specific line, not mapped to a shared definition: Starting point of the indirect method.
  2. “Dotations aux amortissements” is an issuer-specific line, not mapped to a shared definition: Add-back.
  3. “Dotations aux provisions et pertes de valeurs” is an issuer-specific line, not mapped to a shared definition: Add-back.
  4. “Variation impôts différés” is an issuer-specific line, not mapped to a shared definition: Add-back.
  5. “Plus ou Moins value de cession” is an issuer-specific line, not mapped to a shared definition: Gains on disposal deducted.
  6. “Marge brute d'autofinancement” is an issuer-specific line, not mapped to a shared definition: Subtotal: cash earnings before working-capital changes.
  7. “Variation du Besoin en Fonds de Roulement” is an issuer-specific line, not mapped to a shared definition: Change in working capital.
  8. “Variation de l'actif courant” is an issuer-specific line, not mapped to a shared definition: Within the working-capital change.
  9. “Variation du passif courant” is an issuer-specific line, not mapped to a shared definition: Within the working-capital change.
  10. Printed under different labels across filings: “Flux de trésorerie prevenant des opérations d'investissem”; “Flux de trésorerie prevenant des opérations d'investissement”.
  11. “Variation des Titres de participation” is an issuer-specific line, not mapped to a shared definition: Investing.
  12. “Incidence des variations de périmètre” is an issuer-specific line, not mapped to a shared definition: Investing.
  13. “Créances rattachées à des participations” is an issuer-specific line, not mapped to a shared definition: Investing (printed '-' in both years).
  14. “Variation des placements (DAT)” is an issuer-specific line, not mapped to a shared definition: Investing: term deposits.
  15. Printed under different labels across filings: “Flux de trésorerie prevenant des opérations de financemel”; “Flux de trésorerie prevenant des opérations de financement”.
  16. “Compte courant d'associés” is an issuer-specific line, not mapped to a shared definition: Financing.
  17. “Augmentation de capital” is an issuer-specific line, not mapped to a shared definition: Financing.
  18. “Variation prêts et autres actifs financiers non courants” is an issuer-specific line, not mapped to a shared definition: Printed among financing flows.
  19. “Variation des dettes à long terme” is an issuer-specific line, not mapped to a shared definition: Financing (printed '-' in both years).
  20. Not reported in this filing: Not printed: the FY2025 tableau des flux de trésorerie consolidés (p39, image page) prints financing lines 'Emprunts', 'Remboursement Emprunts', 'Compte courant d'associés', 'Augmentation de capital', 'Variation prêts et autres actifs financiers non courants' and 'Dividendes payés' (investing: acquisitions/cessions d'immobilisations, titres de participation, variations de périmètre, créances rattachées, placements DAT); there is no 'Variation des dettes à long terme' line. Checked on the page image (the stored text layer of these pages holds only headings).
  21. “Variation des dettes à court terme” is an issuer-specific line, not mapped to a shared definition: Financing (printed '-' in both years).
  22. Not reported in this filing: Not printed: the FY2025 tableau des flux de trésorerie consolidés (p39, image page) prints financing lines 'Emprunts', 'Remboursement Emprunts', 'Compte courant d'associés', 'Augmentation de capital', 'Variation prêts et autres actifs financiers non courants' and 'Dividendes payés' (investing: acquisitions/cessions d'immobilisations, titres de participation, variations de périmètre, créances rattachées, placements DAT); there is no 'Variation des dettes à court terme' line. Checked on the page image (the stored text layer of these pages holds only headings).
  23. “Variation Intérêts courus non échus (compte 518)” is an issuer-specific line, not mapped to a shared definition: Financing: change in accrued interest not yet due.
  24. Not reported in this filing: Not printed: the FY2025 tableau des flux de trésorerie consolidés (p39, image page) prints financing lines 'Emprunts', 'Remboursement Emprunts', 'Compte courant d'associés', 'Augmentation de capital', 'Variation prêts et autres actifs financiers non courants' and 'Dividendes payés' (investing: acquisitions/cessions d'immobilisations, titres de participation, variations de périmètre, créances rattachées, placements DAT); there is no 'Variation Intérêts courus non échus' line. Checked on the page image (the stored text layer of these pages holds only headings).
  25. “Subvention reçue” is an issuer-specific line, not mapped to a shared definition: Financing: grants received (printed '-' in both years).
  26. Not reported in this filing: Not printed: the FY2025 tableau des flux de trésorerie consolidés (p39, image page) prints financing lines 'Emprunts', 'Remboursement Emprunts', 'Compte courant d'associés', 'Augmentation de capital', 'Variation prêts et autres actifs financiers non courants' and 'Dividendes payés' (investing: acquisitions/cessions d'immobilisations, titres de participation, variations de périmètre, créances rattachées, placements DAT); there is no 'Subvention reçue' line. Checked on the page image (the stored text layer of these pages holds only headings).

Per share and shares

Per share and shares. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025; FY2023 — annual report (signed / final), as reported for the year; FY2022 — annual report (signed / final), comparative reported in the annual report for 2023.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filingFY2023Annual reportreported for the yearFY2022Annual reportcomparative in FY2023 filing
Earnings / (loss) per share (per share)31 Not reported in this filing2 Not reported in this filing2 332 333
Profit / (loss) attributable to shareholders (DZD millions)4 9,413 9,529 8,473 8,496
Notes and alternative reported figures (4)
  1. “Bé néfice par action, part du Groupe (DZD)”: mapping to a shared definition is uncertain. Printed as 'Bénéfice par action, part du Groupe (DZD)'; basic or diluted not stated.
  2. Not reported in this filing: Not printed in the statements (p36).
  3. Earnings / (loss) per share: printed as “Bé néfice par action, part du Groupe (DZD)”.
  4. Profit / (loss) attributable to shareholders: printed as “Dont Part du Groupe”.

Segments

Segment data not yet collected for this company in the pilot.

Dividends

Proposed or recommended, declared and paid are different events and are kept apart. A statement that no dividend was proposed does not mean none was paid.

Dividend events, the issuer's wording, and amounts as printed
Year endedEventWording as printedAmountUnitSource
31 Dec 2025 Dividends paid (cash flow statement) Dividendes payés (4,084) DZD millions Annual report, p39
31 Dec 2024 Dividends paid (cash flow statement) Dividendes payés (4,594) DZD millions Annual report, p39
31 Dec 2023 Dividends paid (cash flow statement) Dividendes payés (3,420) DZD millions Annual report, p40
31 Dec 2022 Dividends paid (cash flow statement) Dividendes payés (4,466) DZD millions Annual report, p40

Sources

Each filing used on this page, newest period first. Dates are the document's own; the date we retrieved a file is shown separately and is never a publication date.

  • Groupe BIOPHARM Rapport annuel 2025

    Year ended 31 December 2025 · Annual report · signed / final

    Audit: Rabah Berarma and Dr Nacir Guettouchi, commissaires aux comptes, unmodified opinion · signed

    Auditor's sign-off: Rabah Berarma (agrément n° 0140); Dr Nacir Guettouchi (agrément n° 0200)

    Final status: The commissaires aux comptes' report on the consolidated statements (PDF pp77-83) certifies them (p79) and is dated 'Alger, le Dimanche Vingt-quatre Mai 2026', signed and stamped by Rabah Berarma and Dr Nacir Guettouchi (p83, page image). The consolidated section's cover reads 'Examinés et arrêtés par le Conseil d'Administration en date du 14 Mai 2025' (p35), a date before the year end; the individual accounts' cover reads 13 Mai 2026 (p53). The board approval date of the consolidated statements is therefore not established.

    Document date
    24 May 2026
    Auditor's report
    24 May 2026
    Board approval
    date printed
    Retrieved by us
    8 Oct 2026 (not a publication date)
    Used for
    statement columns FY2025, FY2024
    Basis
    consolidated statements · DZD millions (printed “en millions de DZD”)
    • Financing cash flows: the printed lines (2 098, (1 213), 14, (0), 19, (4 084); 2024: 35, (2 640), -, -, 23, (4 594)) do not add to the printed total ((3 057); 2024: (7 324)); the totals of the three activities do add to the change in cash ((5 470); 2024: 782). Kept as printed.
    • Board approval date printed for the consolidated statements: '14 Mai 2025' (p35), before the period end; probably a misprint for 2026 (not corrected).
    • Equity: the component lines (capital, reserves, net result 9 469, retained earnings) add to total equity (64 787) including minorities; 'Part de la société consolidante' (64 222) and 'Part des minoritaires' (565) are printed as a split of the same total, so they are not placed within it.
    • Rounding differences of 1 (million) in several printed subtotals are kept as printed.
    • Statement tables are images; the text layer holds only headings. The 'Var.' and '%' columns are not transcribed. Tangible fixed assets and financial fixed assets are printed as headings without totals; their components are transcribed. Total liabilities is not printed.
    Technical details
    File
    86 pages, with a text layer
    SHA-256
    326dc9376813964883d061ebd773f54ec54e7f8144d81e19f6cee04e5c7dc2de
    Entity as printed
    Groupe BIOPHARM; SPA BIOPHARM (société mère) and its subsidiaries
    Issuer copy
    retrieved 2026-10-08T20:39:47Z

  • BIOPHARM Group Rapport annuel 2023

    Year ended 31 December 2023 · Annual report · signed / final

    Audit: Aissa Droua and Lakhdar Seneina, commissaires aux comptes, unmodified opinion · signed

    Auditor's sign-off: Aissa Droua (agrément n° 0193); Lakhdar Seneina (agrément n° 0298)

    Final status: The commissaires aux comptes' report on the consolidated statements (PDF pp78-84) certifies them (p80) and is dated 'Alger, le Dimanche Cinq Mai 2024', signed and stamped by Aissa Droua and Lakhdar Seneina (p84, page image). The consolidated section's cover reads 'Examinés et arrêtés par le Conseil d'Administration en date du 01 Mai 2024' (p36).

    Document date
    5 May 2024
    Auditor's report
    5 May 2024
    Board approval
    1 May 2024
    Retrieved by us
    8 Oct 2026 (not a publication date)
    Used for
    statement columns FY2023, FY2022
    Basis
    consolidated statements · DZD millions (printed “en millions de DZD”)
    • The queue guessed FY2024 (file path 'July2024'); the document is the 2023 annual report, statements at 31 December 2023 with 2022 comparatives.
    • Equity: the component lines add to total equity (54 367) including minorities; 'Part de la société consolidante' (53 934) and 'Part des minoritaires' (433) are printed as a split of the same total, so they are not placed within it.
    • Rounding differences of 1 (million) in some printed subtotals (e.g. investing flows 2023) are kept as printed.
    • Statement tables are images; the text layer holds only headings. The 'Var.' and '%' columns are not transcribed. Tangible and financial fixed assets are printed as headings without totals; their components are transcribed. Total liabilities is not printed. The four starred sub-lines under 'Variation des placements (DAT)' (souscription, remboursement, différence de cours, bons de Trésor) are a breakdown of that line and are not transcribed.
    Technical details
    File
    88 pages, with a text layer
    SHA-256
    a75156b7c0d25c7e2df8c51248c01161b0f7528e36aa46920e93230060c51dfd
    Entity as printed
    BIOPHARM Group; SPA BIOPHARM (société mère) and its subsidiaries
    Issuer copy
    retrieved 2026-10-08T20:40:02Z

Data notes

No figure-level notes beyond those in the tables.

Review status: every figure has been located on its cited source page in an AI-assisted source verification (matched to OCR text of the page image; matched to OCR text and compared cell by cell with the page image; read from the page image) (17 October 2026). Independent review is pending for every figure; automated checks and the AI-assisted verification are not independent review.

Download

Figures shown on this page (CSV) — the same selected figures at their exact printed values, each with its source document, SHA-256, page, selection rule and reading. Independent review of these figures is pending.

· Company methodology and coverage